Name | MLN-4760 |
Description | MLN-4760 is an angiotensin-converting (ACE2) inhibitor(human ACE2;IC50=0.44 nM). It also has excellent selectivity (>5000-fold) versus related enzymes including human testicular ACE (IC50, >100 μM) and bovine carboxypeptidase A (CPDA; IC50, 27 μM). |
In vitro | MLN-4760 displays pIC50 at rhACE2 of 8.5±0.1 and at rhACE of 4.4±0.2. MLN-4760 also shows pIC50 at rhACE2 of 4.7±0.1, 6.9±0.1, and an ACE of 4.4±0.1, 6.2±0.1 in murine heart and mononuclear cells (MNCs), respectively. MLN-4760 potently quenches the cleavage of the 7-Mca-YVADAPK(Dnp) in rhACE2[2]. |
In vivo | MLN-4760 (100 μM, intracerebroventricular infusion for five days) significantly exacerbates neurological function at 4 hours and 3 days post-stroke, without a notable increase in infarct volume[3]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 199 mg/mL (464.62 mM)
|
Keywords | inhibit | Angiotensin-converting Enzyme (ACE) | MLN 4760 | Inhibitor | MLN-4760 | MLN4760 |
Inhibitors Related | Olmesartan Medoxomil | Tranilast | Enalapril Maleate | Azilsartan Methyl Ester | Sacubitril/Valsartan | Azilsartan | Sinapinic Acid | Irbesartan | Losartan | Ramipril | Captopril | Valsartan Methyl Ester |
Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Angiogenesis related Compound Library | Inhibitor Library | NO PAINS Compound Library | Endocrinology-Hormone Compound Library | Bioactive Compounds Library Max | Anti-Hypertension Compound Library |